Given these observations, studies have examined whether the inhibition of the CDK-dependent phosphorylation of RB may have beneficial therapeutic effects in anaplastic thyroid cancer. The gene discussed is RB1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.